Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Zanubrutinib plus obinutuzumab: CLL, SLL & FL

Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the use of zanubrutinib plus obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed/refractory follicular lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.